<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03394001</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R47/2017</org_study_id>
    <nct_id>NCT03394001</nct_id>
  </id_info>
  <brief_title>Wound Infiltration With Ketorolac Versus Lidocaine for Postoperative Analgesia After Total Abdominal Hysterectomy</brief_title>
  <official_title>Wound Infiltration With Ketorolac Versus Lidocaine for Postoperative Analgesia After Total Abdominal Hysterectomy: a Prospective, Randomized, Double-blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to compare wound infiltration with ketorolac versus lidocaine
      for postoperative analgesia in total abdominal hystrectomy (TAH) operation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rescue analgesia time</measure>
    <time_frame>First 24 hours postoperatively</time_frame>
    <description>Time for first analgesia requirement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's pain score</measure>
    <time_frame>First 24 hours postoperatively</time_frame>
    <description>Pain score will be done by visual analog scale (VAS) (minimum 0 = no pain, while maximum 10 cm = worst possible pain). Pain score will be recorded just after extubation (taken as 0 h) and after 1, 2, 4, 6, 12, 18 and 24 h later. Patients will be instructed about the usage of VAS scalebefore the operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total analgesic consumption</measure>
    <time_frame>First 24 hours postoperatively</time_frame>
    <description>Postoperative analgesia will be provided with intramuscular (IM) meperidine 50 mg to both groups when the VAS score is â‰¥4. The total meperidine consumption will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Lidocaine Hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wound infiltration with Lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac tromethamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wound infiltration with Ketorolac</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wound infiltration</intervention_name>
    <description>Before skin closure,the subcutaneous tissue and skin all around the wound will be infiltrated by 20 mL of the drug then closure of the skin will be done.</description>
    <arm_group_label>Lidocaine Hydrochloride</arm_group_label>
    <arm_group_label>Ketorolac tromethamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Hydrochloride</intervention_name>
    <description>20 ml of 1% Lidocaine solution</description>
    <arm_group_label>Lidocaine Hydrochloride</arm_group_label>
    <other_name>Lidocaine Hydrochloride; Lidocaine HCL 50mg/5 ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac tromethamine</intervention_name>
    <description>20 mL of saline with 30 mg ketorolac</description>
    <arm_group_label>Ketorolac tromethamine</arm_group_label>
    <other_name>Adolor; Ketorolac tromethamine 30mg/2ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I and II

          -  Planned for elective TAH with a Pfannenstiel incision

        Exclusion Criteria:

        Patients with the following criteria will be excluded from the study;

          -  ASA physical status more than II

          -  Body mass index (BMI)&gt;35 kg/m2

          -  Previous abdominal surgeries

          -  Malignancy

          -  Individuals with chronic pain

          -  A history of severe systemic disease

          -  A pre-existing neurological or psychiatric illness

          -  Known to be addict on alcohol or drugs

          -  Known allergy to the study drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>11591</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Marwa Mostafa Mohamed Ali Mowafi</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

